Cargando…
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)
General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published d...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047242/ https://www.ncbi.nlm.nih.gov/pubmed/35429382 http://dx.doi.org/10.1093/infdis/jiac146 |
| _version_ | 1784695682840395776 |
|---|---|
| author | Stirrup, Oliver Krutikov, Maria Tut, Gokhan Palmer, Tom Bone, David Bruton, Rachel Fuller, Chris Azmi, Borscha Lancaster, Tara Sylla, Panagiota Kaur, Nayandeep Spalkova, Eliska Bentley, Christopher Amin, Umayr Jadir, Azar Hulme, Samuel Giddings, Rebecca Nacer-Laidi, Hadjer Baynton, Verity Irwin-Singer, Aidan Hayward, Andrew Moss, Paul Copas, Andrew Shallcross, Laura |
| author_facet | Stirrup, Oliver Krutikov, Maria Tut, Gokhan Palmer, Tom Bone, David Bruton, Rachel Fuller, Chris Azmi, Borscha Lancaster, Tara Sylla, Panagiota Kaur, Nayandeep Spalkova, Eliska Bentley, Christopher Amin, Umayr Jadir, Azar Hulme, Samuel Giddings, Rebecca Nacer-Laidi, Hadjer Baynton, Verity Irwin-Singer, Aidan Hayward, Andrew Moss, Paul Copas, Andrew Shallcross, Laura |
| author_sort | Stirrup, Oliver |
| collection | PubMed |
| description | General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups. |
| format | Online Article Text |
| id | pubmed-9047242 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90472422022-04-28 Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI) Stirrup, Oliver Krutikov, Maria Tut, Gokhan Palmer, Tom Bone, David Bruton, Rachel Fuller, Chris Azmi, Borscha Lancaster, Tara Sylla, Panagiota Kaur, Nayandeep Spalkova, Eliska Bentley, Christopher Amin, Umayr Jadir, Azar Hulme, Samuel Giddings, Rebecca Nacer-Laidi, Hadjer Baynton, Verity Irwin-Singer, Aidan Hayward, Andrew Moss, Paul Copas, Andrew Shallcross, Laura J Infect Dis Brief Report General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups. Oxford University Press 2022-04-16 /pmc/articles/PMC9047242/ /pubmed/35429382 http://dx.doi.org/10.1093/infdis/jiac146 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Brief Report Stirrup, Oliver Krutikov, Maria Tut, Gokhan Palmer, Tom Bone, David Bruton, Rachel Fuller, Chris Azmi, Borscha Lancaster, Tara Sylla, Panagiota Kaur, Nayandeep Spalkova, Eliska Bentley, Christopher Amin, Umayr Jadir, Azar Hulme, Samuel Giddings, Rebecca Nacer-Laidi, Hadjer Baynton, Verity Irwin-Singer, Aidan Hayward, Andrew Moss, Paul Copas, Andrew Shallcross, Laura Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI) |
| title | Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI) |
| title_full | Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI) |
| title_fullStr | Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI) |
| title_full_unstemmed | Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI) |
| title_short | Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI) |
| title_sort | severe acute respiratory syndrome coronavirus 2 anti-spike antibody levels following second dose of chadox1 ncov-19 or bnt162b2 vaccine in residents of long-term care facilities in england (vivaldi) |
| topic | Brief Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047242/ https://www.ncbi.nlm.nih.gov/pubmed/35429382 http://dx.doi.org/10.1093/infdis/jiac146 |
| work_keys_str_mv | AT stirrupoliver severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT krutikovmaria severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT tutgokhan severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT palmertom severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT bonedavid severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT brutonrachel severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT fullerchris severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT azmiborscha severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT lancastertara severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT syllapanagiota severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT kaurnayandeep severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT spalkovaeliska severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT bentleychristopher severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT aminumayr severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT jadirazar severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT hulmesamuel severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT giddingsrebecca severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT nacerlaidihadjer severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT bayntonverity severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT irwinsingeraidan severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT haywardandrew severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT mosspaul severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT copasandrew severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi AT shallcrosslaura severeacuterespiratorysyndromecoronavirus2antispikeantibodylevelsfollowingseconddoseofchadox1ncov19orbnt162b2vaccineinresidentsoflongtermcarefacilitiesinenglandvivaldi |